Oldest pages

Jump to navigation Jump to search

Showing below up to 500 results in range #51 to #550.

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

  1. ICRP Publication 107‏‎ (14:58, 10 May 2019)
  2. ICRP Publication 106‏‎ (14:58, 10 May 2019)
  3. ICRP Publication 105‏‎ (14:58, 10 May 2019)
  4. ICRP Publication 104‏‎ (14:59, 10 May 2019)
  5. ICRP Publication 102‏‎ (14:59, 10 May 2019)
  6. ICRP Publication 101‏‎ (14:59, 10 May 2019)
  7. ICRP Publication 101a‏‎ (15:01, 10 May 2019)
  8. ICRP Publication 101b‏‎ (15:01, 10 May 2019)
  9. ICRP Publication 100‏‎ (15:01, 10 May 2019)
  10. ICRP Publication 99‏‎ (15:02, 10 May 2019)
  11. ICRP Publication 98‏‎ (15:03, 10 May 2019)
  12. ICRP Publication 97‏‎ (15:03, 10 May 2019)
  13. ICRP Publication 96‏‎ (15:03, 10 May 2019)
  14. ICRP Publication 95‏‎ (15:04, 10 May 2019)
  15. ICRP Publication 94‏‎ (15:04, 10 May 2019)
  16. ICRP Publication 93‏‎ (15:04, 10 May 2019)
  17. ICRP Publication 92‏‎ (15:05, 10 May 2019)
  18. ICRP Publication 91‏‎ (15:05, 10 May 2019)
  19. ICRP Publication 90‏‎ (15:06, 10 May 2019)
  20. ICRP Publication 89‏‎ (15:06, 10 May 2019)
  21. ICRP Publication 88‏‎ (15:07, 10 May 2019)
  22. ICRP Publication 87‏‎ (15:07, 10 May 2019)
  23. ICRP Publication 86‏‎ (15:07, 10 May 2019)
  24. ICRP Publication 85‏‎ (15:07, 10 May 2019)
  25. ICRP Publication 84‏‎ (15:08, 10 May 2019)
  26. ICRP Publication 83‏‎ (15:08, 10 May 2019)
  27. ICRP Publication 82‏‎ (15:09, 10 May 2019)
  28. ICRP Publication 81‏‎ (15:09, 10 May 2019)
  29. ICRP Publication 80‏‎ (15:10, 10 May 2019)
  30. ICRP Publication 79‏‎ (15:10, 10 May 2019)
  31. ICRP Publication 78‏‎ (15:10, 10 May 2019)
  32. ICRP Publication 77‏‎ (15:11, 10 May 2019)
  33. ICRP Publication 76‏‎ (15:13, 10 May 2019)
  34. ICRP Publication 75‏‎ (15:14, 10 May 2019)
  35. ICRP Publication 74‏‎ (15:14, 10 May 2019)
  36. ICRP Publication 73‏‎ (15:14, 10 May 2019)
  37. ICRP Publication 72‏‎ (15:15, 10 May 2019)
  38. ICRP Publication 71‏‎ (15:15, 10 May 2019)
  39. ICRP Publication 70‏‎ (15:15, 10 May 2019)
  40. ICRP Publication 69‏‎ (15:16, 10 May 2019)
  41. ICRP Publication 68‏‎ (15:16, 10 May 2019)
  42. ICRP Publication 67‏‎ (15:17, 10 May 2019)
  43. ICRP Publication 66‏‎ (15:17, 10 May 2019)
  44. ICRP Publication 65‏‎ (15:17, 10 May 2019)
  45. ICRP Publication 64‏‎ (15:19, 10 May 2019)
  46. ICRP Publication 63‏‎ (15:20, 10 May 2019)
  47. ICRP Publication 62‏‎ (15:20, 10 May 2019)
  48. ICRP Publication 61‏‎ (15:20, 10 May 2019)
  49. ICRP Publication 60‏‎ (15:21, 10 May 2019)
  50. ICRP Publication 59‏‎ (15:22, 10 May 2019)
  51. ICRP Publication 58‏‎ (15:24, 10 May 2019)
  52. ICRP Publication 57‏‎ (15:25, 10 May 2019)
  53. ICRP Publication 56‏‎ (15:25, 10 May 2019)
  54. ICRP Publication 55‏‎ (15:25, 10 May 2019)
  55. ICRP Publication 54‏‎ (15:26, 10 May 2019)
  56. ICRP Publication 53‏‎ (15:26, 10 May 2019)
  57. ICRP Publication 52‏‎ (15:27, 10 May 2019)
  58. ICRP Publication 51‏‎ (15:27, 10 May 2019)
  59. ICRP Publication 50‏‎ (15:27, 10 May 2019)
  60. ICRP Publication 49‏‎ (15:28, 10 May 2019)
  61. ICRP Publication 48‏‎ (15:28, 10 May 2019)
  62. ICRP Publication 47‏‎ (15:28, 10 May 2019)
  63. ICRP Publication 46‏‎ (15:29, 10 May 2019)
  64. ICRP Publication 45‏‎ (15:29, 10 May 2019)
  65. ICRP Publication 44‏‎ (15:29, 10 May 2019)
  66. ICRP Publication 43‏‎ (15:30, 10 May 2019)
  67. ICRP Publication 42‏‎ (15:30, 10 May 2019)
  68. ICRP Publication 41‏‎ (15:30, 10 May 2019)
  69. ICRP Publication 40‏‎ (15:30, 10 May 2019)
  70. ICRP Publication 39‏‎ (15:31, 10 May 2019)
  71. ICRP Publication 38‏‎ (15:31, 10 May 2019)
  72. ICRP Publication 37‏‎ (15:31, 10 May 2019)
  73. ICRP Publication 36‏‎ (15:31, 10 May 2019)
  74. ICRP Publication 35‏‎ (15:31, 10 May 2019)
  75. ICRP Publication 34‏‎ (15:32, 10 May 2019)
  76. ICRP Publication 33‏‎ (15:32, 10 May 2019)
  77. ICRP Publication 32‏‎ (15:32, 10 May 2019)
  78. ICRP Publication 31‏‎ (15:32, 10 May 2019)
  79. ICRP Publication 30‏‎ (15:33, 10 May 2019)
  80. ICRP Publication 30 (Part 1)‏‎ (15:35, 10 May 2019)
  81. ICRP Publication 30 (Part 2)‏‎ (15:35, 10 May 2019)
  82. ICRP Publication 30 (Part 3)‏‎ (15:36, 10 May 2019)
  83. ICRP Publication 30 (Part 4)‏‎ (15:36, 10 May 2019)
  84. ICRP Publication 30 (Index)‏‎ (15:42, 10 May 2019)
  85. ICRP Publication 30 (Supplement to Part 1)‏‎ (15:43, 10 May 2019)
  86. ICRP Publication 30 (Supplement to Part 2)‏‎ (15:44, 10 May 2019)
  87. ICRP Publication 30 (Supplement A to Part 3)‏‎ (15:44, 10 May 2019)
  88. ICRP Publication 30 (Supplement B to Part 3)‏‎ (15:45, 10 May 2019)
  89. ICRP Publication 29‏‎ (15:46, 10 May 2019)
  90. ICRP Publication 28‏‎ (15:46, 10 May 2019)
  91. ICRP Publication 27‏‎ (15:46, 10 May 2019)
  92. ICRP Publication 26‏‎ (15:46, 10 May 2019)
  93. ICRP Publication 25‏‎ (15:46, 10 May 2019)
  94. ICRP Publication 24‏‎ (15:47, 10 May 2019)
  95. ICRP Publication 23‏‎ (15:47, 10 May 2019)
  96. ICRP Publication 22‏‎ (15:47, 10 May 2019)
  97. ICRP Publication 21‏‎ (15:47, 10 May 2019)
  98. ICRP Publication 20‏‎ (15:47, 10 May 2019)
  99. ICRP Publication 19‏‎ (15:48, 10 May 2019)
  100. ICRP Publication 18‏‎ (15:48, 10 May 2019)
  101. ICRP Publication 17‏‎ (15:48, 10 May 2019)
  102. ICRP Publication 16‏‎ (15:48, 10 May 2019)
  103. ICRP Publication 15‏‎ (15:49, 10 May 2019)
  104. ICRP Publication 14‏‎ (15:49, 10 May 2019)
  105. ICRP Publication 13‏‎ (15:49, 10 May 2019)
  106. ICRP Publication 12‏‎ (15:49, 10 May 2019)
  107. ICRP Publication 11‏‎ (15:50, 10 May 2019)
  108. ICRP Publication 10‏‎ (15:50, 10 May 2019)
  109. ICRP Publication 10A‏‎ (15:50, 10 May 2019)
  110. ICRP Publication 9‏‎ (15:51, 10 May 2019)
  111. ICRP Publication 8‏‎ (15:51, 10 May 2019)
  112. ICRP Publication 7‏‎ (15:51, 10 May 2019)
  113. ICRP Publication 6‏‎ (15:52, 10 May 2019)
  114. ICRP Publication 5‏‎ (15:52, 10 May 2019)
  115. ICRP Publication 4‏‎ (15:52, 10 May 2019)
  116. ICRP Publication 3‏‎ (15:52, 10 May 2019)
  117. ICRP Publication 2‏‎ (15:52, 10 May 2019)
  118. ICRP Publication 1‏‎ (15:53, 10 May 2019)
  119. 1959 Decisions‏‎ (15:54, 10 May 2019)
  120. 1956 Recommendations‏‎ (15:56, 10 May 2019)
  121. 1954 Recommendations‏‎ (15:56, 10 May 2019)
  122. 1950 Recommendations‏‎ (15:57, 10 May 2019)
  123. 1937 Recommendations‏‎ (15:58, 10 May 2019)
  124. 1934 Recommendations‏‎ (15:58, 10 May 2019)
  125. 1931 Recommendations‏‎ (15:58, 10 May 2019)
  126. 1928 Recommendations‏‎ (15:59, 10 May 2019)
  127. ICRP‏‎ (20:10, 4 June 2019)
  128. International Commission on Radiological Protection‏‎ (20:12, 4 June 2019)
  129. ICRP Supporting Guidance 2‏‎ (18:39, 5 June 2019)
  130. Effects of Exposure‏‎ (17:22, 7 June 2019)
  131. System of radiological protection‏‎ (17:47, 10 June 2019)
  132. Objectives of Radiological Protection‏‎ (19:46, 20 June 2019)
  133. Fundamental Principles of Radiological Protection‏‎ (19:46, 20 June 2019)
  134. Exposure Categories and Situations‏‎ (19:46, 20 June 2019)
  135. Dose limits‏‎ (19:47, 20 June 2019)
  136. Cell death‏‎ (13:46, 12 September 2019)
  137. Programmed cell death‏‎ (13:50, 12 September 2019)
  138. Senescence‏‎ (13:53, 12 September 2019)
  139. Bioassay‏‎ (15:40, 12 September 2019)
  140. Medical exposure‏‎ (17:13, 12 September 2019)
  141. Patient entrance reference point‏‎ (17:15, 12 September 2019)
  142. Solar wind‏‎ (17:23, 12 September 2019)
  143. Acceptance test‏‎ (17:24, 12 September 2019)
  144. Accountability‏‎ (17:25, 12 September 2019)
  145. Action Level‏‎ (17:26, 12 September 2019)
  146. Active (red) bone marrow‏‎ (17:26, 12 September 2019)
  147. Adventitious‏‎ (17:27, 12 September 2019)
  148. Aerodynamic diameter‏‎ (17:29, 12 September 2019)
  149. Air-kerma rate constant‏‎ (17:31, 12 September 2019)
  150. Air-kerma, entrance surface‏‎ (17:31, 12 September 2019)
  151. Air-kerma, incident‏‎ (17:32, 12 September 2019)
  152. Air-kerma, product‏‎ (17:33, 12 September 2019)
  153. Alimentary tract transfer factor‏‎ (17:34, 12 September 2019)
  154. Alpha decay‏‎ (17:35, 12 September 2019)
  155. Alveolar-interstitial region‏‎ (17:35, 12 September 2019)
  156. Angiogenesis‏‎ (17:35, 12 September 2019)
  157. Annihilation photons‏‎ (17:36, 12 September 2019)
  158. Annual dose‏‎ (17:36, 12 September 2019)
  159. Area monitoring‏‎ (17:37, 12 September 2019)
  160. Auger transition‏‎ (17:37, 12 September 2019)
  161. Authorization‏‎ (17:38, 12 September 2019)
  162. Authorized limit‏‎ (17:38, 12 September 2019)
  163. Autoimmune disease‏‎ (17:39, 12 September 2019)
  164. Autonomy‏‎ (17:39, 12 September 2019)
  165. Averted dose‏‎ (17:40, 12 September 2019)
  166. Wisdom‏‎ (17:43, 12 September 2019)
  167. Waste disposal‏‎ (17:43, 12 September 2019)
  168. Background dose (rate)‏‎ (18:55, 12 September 2019)
  169. Basal cell‏‎ (18:56, 12 September 2019)
  170. Benthic‏‎ (18:57, 12 September 2019)
  171. Beta-minus decay‏‎ (18:57, 12 September 2019)
  172. Beta-plus decay‏‎ (18:58, 12 September 2019)
  173. Biomedical research volunteer‏‎ (18:58, 12 September 2019)
  174. Bioturbation‏‎ (18:59, 12 September 2019)
  175. Bone marrow‏‎ (18:59, 12 September 2019)
  176. Bradycardia‏‎ (18:59, 12 September 2019)
  177. Branching fraction‏‎ (18:59, 12 September 2019)
  178. Bronchial region‏‎ (19:00, 12 September 2019)
  179. Bystander effect‏‎ (19:00, 12 September 2019)
  180. Qualified expert‏‎ (19:03, 12 September 2019)
  181. Occupational exposure‏‎ (19:07, 12 September 2019)
  182. Orphan source‏‎ (19:07, 12 September 2019)
  183. Oversight‏‎ (19:07, 12 September 2019)
  184. Cardiac arrhythmias‏‎ (19:15, 12 September 2019)
  185. Cardiac valve diseases‏‎ (19:16, 12 September 2019)
  186. Cardiomyopathy‏‎ (19:16, 12 September 2019)
  187. Cardioverter-defibrillator‏‎ (19:16, 12 September 2019)
  188. Chronic exposure‏‎ (19:17, 12 September 2019)
  189. Class SR-0 gases‏‎ (19:17, 12 September 2019)
  190. Class SR-1 gases‏‎ (19:17, 12 September 2019)
  191. Class SR-2 gases‏‎ (19:18, 12 September 2019)
  192. Clearance level‏‎ (19:19, 12 September 2019)
  193. Clonogenic cells‏‎ (19:19, 12 September 2019)
  194. Clonogenic survival‏‎ (19:19, 12 September 2019)
  195. Co-expertise‏‎ (19:19, 12 September 2019)
  196. Colony‏‎ (19:20, 12 September 2019)
  197. Committed effective dose‏‎ (19:20, 12 September 2019)
  198. Committed equivalent dose‏‎ (19:20, 12 September 2019)
  199. Complex tissues‏‎ (19:21, 12 September 2019)
  200. Computed tomography dose index‏‎ (19:21, 12 September 2019)
  201. Connective tissue‏‎ (19:21, 12 September 2019)
  202. Consequential late effects‏‎ (19:21, 12 September 2019)
  203. Constancy test‏‎ (19:21, 12 September 2019)
  204. Contamination‏‎ (19:22, 12 September 2019)
  205. Coronary heart disease‏‎ (19:23, 12 September 2019)
  206. Cost-benefit analysis‏‎ (19:24, 12 September 2019)
  207. Coster-Kronig transition‏‎ (19:25, 12 September 2019)
  208. Curie‏‎ (19:25, 12 September 2019)
  209. Cytokines‏‎ (19:26, 12 September 2019)
  210. Decay constant‏‎ (19:28, 12 September 2019)
  211. Decommissioning‏‎ (19:28, 12 September 2019)
  212. Decontamination‏‎ (19:29, 12 September 2019)
  213. Decontamination factor‏‎ (19:29, 12 September 2019)
  214. Deontological Ethics‏‎ (19:30, 12 September 2019)
  215. Diastasis‏‎ (19:30, 12 September 2019)
  216. Dichotomous‏‎ (19:31, 12 September 2019)
  217. Differentiation‏‎ (19:31, 12 September 2019)
  218. In vivo radiobioassay‏‎ (19:32, 12 September 2019)
  219. Disposal‏‎ (19:33, 12 September 2019)
  220. DNA damage signalling‏‎ (19:33, 12 September 2019)
  221. Dose constraint‏‎ (19:35, 12 September 2019)
  222. Dose criteria‏‎ (19:35, 12 September 2019)
  223. Dose limit‏‎ (19:36, 12 September 2019)
  224. Dose per unit intake coefficient‏‎ (19:37, 12 September 2019)
  225. Dose rate‏‎ (19:38, 12 September 2019)
  226. Dose rate effectiveness factor‏‎ (19:38, 12 September 2019)
  227. Dose-rate effect‏‎ (19:39, 12 September 2019)
  228. Dose-threshold‏‎ (19:40, 12 September 2019)
  229. Early normal tissue responses‏‎ (19:43, 12 September 2019)
  230. Edema‏‎ (19:44, 12 September 2019)
  231. Effect Dose 50‏‎ (19:45, 12 September 2019)
  232. Effective charge number‏‎ (19:46, 12 September 2019)
  233. Effective dose equivalent‏‎ (19:47, 12 September 2019)
  234. Effective half-life‏‎ (19:49, 12 September 2019)
  235. Electron-capture decay‏‎ (19:49, 12 September 2019)
  236. Electrophysiology‏‎ (19:51, 12 September 2019)
  237. Emergency‏‎ (19:52, 12 September 2019)
  238. Emergency exposure situation‏‎ (19:52, 12 September 2019)
  239. Emergency plan‏‎ (19:53, 12 September 2019)
  240. Emergency preparedness‏‎ (19:53, 12 September 2019)
  241. Emergency procedures‏‎ (19:53, 12 September 2019)
  242. Endogeneous excretion‏‎ (19:54, 12 September 2019)
  243. Environmental exposure‏‎ (19:55, 12 September 2019)
  244. Environmental radiation protection‏‎ (19:55, 12 September 2019)
  245. Epithelium‏‎ (19:56, 12 September 2019)
  246. Erythropoietin‏‎ (19:57, 12 September 2019)
  247. Ethics‏‎ (19:58, 12 September 2019)
  248. Exempt waste‏‎ (19:59, 12 September 2019)
  249. Exemption level‏‎ (19:59, 12 September 2019)
  250. Existing exposure situation‏‎ (20:00, 12 September 2019)
  251. Exponential survival curve‏‎ (20:01, 12 September 2019)
  252. Exposure, external or internal‏‎ (20:01, 12 September 2019)
  253. Exposure situation‏‎ (20:02, 12 September 2019)
  254. Habitual mouth breather‏‎ (12:42, 13 September 2019)
  255. Habitual nose breather‏‎ (12:42, 13 September 2019)
  256. Half-life, physical‏‎ (12:43, 13 September 2019)
  257. Hazard‏‎ (12:43, 13 September 2019)
  258. Health Surveillance‏‎ (12:43, 13 September 2019)
  259. Heliosphere‏‎ (12:44, 13 September 2019)
  260. Hierarchical tissues‏‎ (12:44, 13 September 2019)
  261. High level waste‏‎ (12:45, 13 September 2019)
  262. Hormones‏‎ (12:45, 13 September 2019)
  263. Hyperbaric oxygen‏‎ (12:46, 13 September 2019)
  264. Hypertrophic cardiomyopathy‏‎ (12:48, 13 September 2019)
  265. Hypoplasia‏‎ (12:48, 13 September 2019)
  266. Immune system‏‎ (12:49, 13 September 2019)
  267. Incident‏‎ (12:50, 13 September 2019)
  268. Inclusiveness‏‎ (12:50, 13 September 2019)
  269. Individual decontamination‏‎ (12:50, 13 September 2019)
  270. Individual monitoring‏‎ (12:51, 13 September 2019)
  271. Individual-related‏‎ (12:51, 13 September 2019)
  272. Inhalability‏‎ (12:53, 13 September 2019)
  273. Inner bremsstrahlung‏‎ (12:53, 13 September 2019)
  274. Institutional control‏‎ (12:54, 13 September 2019)
  275. Intermediate level waste‏‎ (12:54, 13 September 2019)
  276. Internal conversion electron‏‎ (12:56, 13 September 2019)
  277. Interphase death‏‎ (12:56, 13 September 2019)
  278. Intervention Level‏‎ (12:56, 13 September 2019)
  279. Interventional procedure‏‎ (12:57, 13 September 2019)
  280. Iso-effect plots‏‎ (12:58, 13 September 2019)
  281. Isomers‏‎ (12:58, 13 September 2019)
  282. Isotropic geometry‏‎ (12:58, 13 September 2019)
  283. Itinerant (radiation) worker‏‎ (12:59, 13 September 2019)
  284. Latent time/period or latency interval‏‎ (13:01, 13 September 2019)
  285. Limitation of dose‏‎ (13:01, 13 September 2019)
  286. Lineal energy‏‎ (13:02, 13 September 2019)
  287. Linear-non-threshold model‏‎ (13:03, 13 September 2019)
  288. Low level waste‏‎ (13:08, 13 September 2019)
  289. Lymphatic system‏‎ (13:08, 13 September 2019)
  290. Macrophage colony stimulating factor‏‎ (13:08, 13 September 2019)
  291. Magnetosphere‏‎ (13:09, 13 September 2019)
  292. Member of the public‏‎ (13:10, 13 September 2019)
  293. Mendelian diseases‏‎ (13:10, 13 September 2019)
  294. Mitigation‏‎ (13:10, 13 September 2019)
  295. Multistage tumorigenesis‏‎ (13:11, 13 September 2019)
  296. Myocardial perfusion‏‎ (13:12, 13 September 2019)
  297. Myocardial stress test‏‎ (13:13, 13 September 2019)
  298. Naturally occurring radioactive material‏‎ (13:14, 13 September 2019)
  299. Necrosis‏‎ (13:14, 13 September 2019)
  300. Neurological syndrome‏‎ (13:14, 13 September 2019)
  301. Neurovascular syndrome‏‎ (13:15, 13 September 2019)
  302. Non-sphericity parameter‏‎ (13:16, 13 September 2019)
  303. Nuclear track detectors‏‎ (13:17, 13 September 2019)
  304. Particle radiance‏‎ (13:28, 13 September 2019)
  305. Peak skin dose‏‎ (13:28, 13 September 2019)
  306. Pelagic‏‎ (13:29, 13 September 2019)
  307. Percutaneous coronary intervention‏‎ (13:29, 13 September 2019)
  308. Pericarditis‏‎ (13:29, 13 September 2019)
  309. Pharynx‏‎ (13:30, 13 September 2019)
  310. Planned exposure situation‏‎ (13:30, 13 September 2019)
  311. Platelet-derived growth factor‏‎ (13:30, 13 September 2019)
  312. Practical radiological protection culture‏‎ (13:32, 13 September 2019)
  313. Prevailing circumstances‏‎ (13:32, 13 September 2019)
  314. Principle of application of dose limits‏‎ (13:32, 13 September 2019)
  315. Principle of justification‏‎ (13:33, 13 September 2019)
  316. Principle of optimisation‏‎ (13:33, 13 September 2019)
  317. Procedural values‏‎ (13:34, 13 September 2019)
  318. Progenitor cell‏‎ (13:35, 13 September 2019)
  319. Projected dose‏‎ (13:36, 13 September 2019)
  320. Protection strategy‏‎ (13:37, 13 September 2019)
  321. Protective action‏‎ (13:37, 13 September 2019)
  322. Protective action guide‏‎ (13:38, 13 September 2019)
  323. Public exposure‏‎ (13:39, 13 September 2019)
  324. Radiation modifier‏‎ (13:41, 13 September 2019)
  325. Radiation safety officer‏‎ (13:42, 13 September 2019)
  326. Radiation worker‏‎ (13:44, 13 September 2019)
  327. Radioactive dispersion device‏‎ (13:44, 13 September 2019)
  328. Radioactive source‏‎ (13:45, 13 September 2019)
  329. Radioactive substance‏‎ (13:46, 13 September 2019)
  330. Radioactivity‏‎ (13:46, 13 September 2019)
  331. Radiofrequency ablation‏‎ (13:46, 13 September 2019)
  332. Radiographer‏‎ (13:48, 13 September 2019)
  333. Radiological protection principles‏‎ (13:49, 13 September 2019)
  334. Radionuclides of natural origin‏‎ (13:49, 13 September 2019)
  335. Radioresponsiveness‏‎ (13:49, 13 September 2019)
  336. Radiosensitiser‏‎ (13:50, 13 September 2019)
  337. Radiosensitivity, cellular‏‎ (13:50, 13 September 2019)
  338. Reasonableness‏‎ (13:50, 13 September 2019)
  339. Recovery‏‎ (13:51, 13 September 2019)
  340. Recovery responder‏‎ (13:51, 13 September 2019)
  341. Reference bioassay function‏‎ (13:51, 13 September 2019)
  342. Reference biokinetic model‏‎ (13:52, 13 September 2019)
  343. Reference level‏‎ (13:52, 13 September 2019)
  344. Rehabilitation of living conditions‏‎ (13:52, 13 September 2019)
  345. Relocation‏‎ (13:53, 13 September 2019)
  346. Remedial action‏‎ (13:53, 13 September 2019)
  347. Remediation‏‎ (13:53, 13 September 2019)
  348. Repopulation‏‎ (13:54, 13 September 2019)
  349. Representative organism (non-human biota)‏‎ (13:54, 13 September 2019)
  350. Representative person‏‎ (13:54, 13 September 2019)
  351. Reproductive integrity‏‎ (13:55, 13 September 2019)
  352. Residual dose‏‎ (13:55, 13 September 2019)
  353. Respiratory protection‏‎ (13:55, 13 September 2019)
  354. Retrievability‏‎ (13:56, 13 September 2019)
  355. Reversibility‏‎ (13:56, 13 September 2019)
  356. Right to know‏‎ (13:57, 13 September 2019)
  357. Rigidity‏‎ (13:58, 13 September 2019)
  358. Routine monitoring‏‎ (13:58, 13 September 2019)
  359. Safety case‏‎ (13:59, 13 September 2019)
  360. Safety culture‏‎ (13:59, 13 September 2019)
  361. Scintigraphy‏‎ (13:59, 13 September 2019)
  362. Self-help protection‏‎ (14:00, 13 September 2019)
  363. Slow repair‏‎ (14:01, 13 September 2019)
  364. Solar cosmic radiation‏‎ (14:01, 13 September 2019)
  365. Solar cycle‏‎ (14:01, 13 September 2019)
  366. Solar particle event‏‎ (14:01, 13 September 2019)
  367. Source term‏‎ (14:02, 13 September 2019)
  368. Source-related‏‎ (14:02, 13 September 2019)
  369. South Atlantic anomaly‏‎ (14:03, 13 September 2019)
  370. Special (non-routine) monitoring‏‎ (14:03, 13 September 2019)
  371. Spontaneous fission‏‎ (14:03, 13 September 2019)
  372. Stakeholder‏‎ (14:04, 13 September 2019)
  373. Stenosis‏‎ (14:04, 13 September 2019)
  374. Storage‏‎ (14:04, 13 September 2019)
  375. Subcutaneous tissue‏‎ (14:05, 13 September 2019)
  376. Substantial radiation dose level‏‎ (14:05, 13 September 2019)
  377. Systemic model‏‎ (14:06, 13 September 2019)
  378. Tachycardia‏‎ (14:10, 13 September 2019)
  379. Target region‏‎ (14:10, 13 September 2019)
  380. Target tissue‏‎ (14:10, 13 September 2019)
  381. Telangiectasia‏‎ (14:11, 13 September 2019)
  382. Threshold dose for tissue reactions‏‎ (14:11, 13 September 2019)
  383. Thyroid blocking‏‎ (14:11, 13 September 2019)
  384. Time factor‏‎ (14:11, 13 September 2019)
  385. Tissue equivalent material‏‎ (14:12, 13 September 2019)
  386. Tolerability‏‎ (14:12, 13 September 2019)
  387. Track structure‏‎ (14:13, 13 September 2019)
  388. Transfer compartment‏‎ (14:14, 13 September 2019)
  389. Transfer rate‏‎ (14:14, 13 September 2019)
  390. Transforming growth factor‏‎ (14:15, 13 September 2019)
  391. Transparency‏‎ (14:15, 13 September 2019)
  392. Trapped particles‏‎ (14:16, 13 September 2019)
  393. Types of materials‏‎ (14:16, 13 September 2019)
  394. Application of ionising radiation in healthcare (old)‏‎ (18:00, 9 October 2019)
  395. Information for patients, family members, carers and the public (old)‏‎ (18:00, 9 October 2019)
  396. Information for healthcare providers (old)‏‎ (18:00, 9 October 2019)
  397. Application of ionising radiation in healthcare‏‎ (18:04, 9 October 2019)
  398. Information for patients, family members, carers and the public‏‎ (18:11, 9 October 2019)
  399. Information for healthcare providers‏‎ (18:21, 9 October 2019)
  400. ICRPædia Guides‏‎ (18:33, 9 October 2019)
  401. List of ICRP Publications on Radiological Protection in Healthcare‏‎ (13:57, 17 October 2019)
  402. Guide to Radiological Protection in Healthcare‏‎ (13:59, 17 October 2019)
  403. The System of Radiological Protection‏‎ (15:15, 23 October 2019)
  404. Quotes from Publications on the System of Radiological Protection‏‎ (17:58, 23 October 2019)
  405. Guide to the System of Radiological Protection‏‎ (15:40, 24 October 2019)
  406. General Information on Radon‏‎ (12:41, 30 October 2019)
  407. System Of Radiation Protection Overview‏‎ (15:02, 4 November 2019)
  408. System of radiation protection module 2‏‎ (15:11, 4 November 2019)
  409. Absorbed, Equivalent, and Effective Dose‏‎ (21:54, 21 November 2019)
  410. Radon For Governments and Employers‏‎ (18:19, 3 December 2019)
  411. Radon For Homeowners and Residents‏‎ (18:19, 3 December 2019)
  412. Guide to Radon‏‎ (07:37, 5 February 2020)
  413. Main Page‏‎ (12:31, 18 November 2020)
  414. Additive risk projection model‏‎ (20:28, 24 February 2021)
  415. Attributable risk‏‎ (20:30, 24 February 2021)
  416. Dicentric chromosome‏‎ (20:31, 24 February 2021)
  417. Effect modifier‏‎ (20:32, 24 February 2021)
  418. Hereditary effect‏‎ (20:33, 24 February 2021)
  419. Low dose‏‎ (20:33, 24 February 2021)
  420. Low dose rate‏‎ (20:35, 24 February 2021)
  421. Multiplicative risk projection model‏‎ (20:36, 24 February 2021)
  422. Ring chromosome‏‎ (20:38, 24 February 2021)
  423. Severe deterministic injury‏‎ (20:38, 24 February 2021)
  424. Somatic effect‏‎ (20:39, 24 February 2021)
  425. Transgenerational effect‏‎ (20:40, 24 February 2021)
  426. Detriment-adjusted risk‏‎ (20:42, 24 February 2021)
  427. Elemental dose‏‎ (20:44, 24 February 2021)
  428. Multistage carcinogenesis model‏‎ (20:50, 24 February 2021)
  429. Mutation component‏‎ (20:51, 24 February 2021)
  430. Oncogene‏‎ (20:52, 24 February 2021)
  431. Population risk‏‎ (20:53, 24 February 2021)
  432. Potentially lethal damage repair‏‎ (20:54, 24 February 2021)
  433. Radiation risk‏‎ (20:55, 24 February 2021)
  434. Relative life lost‏‎ (20:56, 24 February 2021)
  435. Risk model‏‎ (20:57, 24 February 2021)
  436. Sublethal damage repair‏‎ (20:58, 24 February 2021)
  437. Transfer of risk‏‎ (20:59, 24 February 2021)
  438. Tumour suppressor gene‏‎ (21:00, 24 February 2021)
  439. Acute radiation syndrome‏‎ (21:40, 24 February 2021)
  440. Adaptive response‏‎ (21:42, 24 February 2021)
  441. Α/β value‏‎ (21:46, 24 February 2021)
  442. ΓH2AX foci‏‎ (21:46, 24 February 2021)
  443. Informed consent‏‎ (21:49, 24 February 2021)
  444. Supervised area‏‎ (21:51, 24 February 2021)
  445. Access control‏‎ (21:52, 24 February 2021)
  446. Acute exposure‏‎ (21:54, 24 February 2021)
  447. Adventitious source‏‎ (21:55, 24 February 2021)
  448. Authorised discharge‏‎ (21:57, 24 February 2021)
  449. Backscatter factor‏‎ (21:59, 24 February 2021)
  450. Best available techniques‏‎ (22:00, 24 February 2021)
  451. Disposal facility‏‎ (22:02, 24 February 2021)
  452. Dose modifying factor‏‎ (22:03, 24 February 2021)
  453. Exposure pathway‏‎ (22:05, 24 February 2021)
  454. Radiological controlled area‏‎ (22:07, 24 February 2021)
  455. Life Span Study‏‎ (22:10, 24 February 2021)
  456. Detriment‏‎ (19:17, 25 February 2021)
  457. Baseline disease rates‏‎ (19:29, 25 February 2021)
  458. Biomarker‏‎ (19:31, 25 February 2021)
  459. Case–control study‏‎ (19:33, 25 February 2021)
  460. Deterministic effect‏‎ (19:38, 25 February 2021)
  461. Dose and dose-rate effectiveness factor‏‎ (15:54, 26 February 2021)
  462. Dose-threshold hypothesis‏‎ (15:56, 26 February 2021)
  463. Tissue reaction‏‎ (16:00, 26 February 2021)
  464. Doubling dose‏‎ (17:10, 26 February 2021)
  465. Epigenetic effects‏‎ (17:13, 26 February 2021)
  466. Excess absolute risk‏‎ (17:16, 26 February 2021)
  467. Excess relative risk‏‎ (17:25, 26 February 2021)
  468. Homologous recombination‏‎ (17:26, 26 February 2021)
  469. Incidence‏‎ (17:28, 26 February 2021)
  470. Induced genomic instability‏‎ (17:30, 26 February 2021)
  471. Late normal tissue responses‏‎ (17:31, 26 February 2021)
  472. LD 50/30‏‎ (17:33, 26 February 2021)
  473. Lifetime risk estimates‏‎ (17:42, 26 February 2021)
  474. Linear dose response‏‎ (17:43, 26 February 2021)
  475. Linear-quadratic dose response model‏‎ (17:48, 26 February 2021)
  476. Stochastic effect‏‎ (17:58, 26 February 2021)
  477. Nominal risk coefficient‏‎ (19:29, 26 February 2021)
  478. Non-homologous end joining‏‎ (19:30, 26 February 2021)
  479. Non-targeted effects‏‎ (19:31, 26 February 2021)
  480. Normal tissue complication probability‏‎ (19:33, 26 February 2021)
  481. Pooled analysis‏‎ (19:34, 26 February 2021)
  482. Quasi-threshold dose‏‎ (19:35, 26 February 2021)
  483. Reactive oxygen species‏‎ (19:36, 26 February 2021)
  484. Recovery (cellular or tissue)‏‎ (19:38, 26 February 2021)
  485. Reference Animal and Plant‏‎ (19:43, 26 February 2021)
  486. Relative biological effectiveness‏‎ (20:22, 26 February 2021)
  487. Relative risk‏‎ (20:25, 26 February 2021)
  488. Risk coefficient‏‎ (20:30, 26 February 2021)
  489. Targeted effects‏‎ (20:32, 26 February 2021)
  490. Translocation‏‎ (20:33, 26 February 2021)
  491. Radiation source‏‎ (21:04, 26 February 2021)
  492. Dose-response function‏‎ (14:57, 28 March 2021)
  493. Tissue weighting factor‏‎ (21:32, 28 March 2021)
  494. Absorption‏‎ (22:15, 28 March 2021)
  495. Activation‏‎ (22:16, 28 March 2021)
  496. Activity‏‎ (22:19, 28 March 2021)
  497. ICRPædia Guide to the System of Radiological Protection‏‎ (21:44, 3 May 2021)
  498. Active detection system‏‎ (19:35, 11 August 2021)
  499. Additional dose‏‎ (19:36, 11 August 2021)
  500. Allometry‏‎ (19:37, 11 August 2021)

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://icrpaedia.org/Special:AncientPages"